{"log_id": 782512132238841706, "direction": 0, "words_result_num": 14, "words_result": [{"probability": {"variance": 0.00068, "average": 0.992428, "min": 0.848561}, "location": {"width": 835, "top": 227, "height": 45, "left": 184}, "words": "(含舒尼替尼、细胞因子或两种药物)后出现疾病进展的mRCC患者中,对比研究了"}, {"probability": {"variance": 0.000104, "average": 0.997223, "min": 0.93627}, "location": {"width": 846, "top": 282, "height": 46, "left": 175}, "words": "阿昔替尼与索拉非尼的有效性和安全性。共204例既往接受过治疗的亚洲患者(包括"}, {"probability": {"variance": 7.4e-05, "average": 0.995937, "min": 0.947101}, "location": {"width": 822, "top": 339, "height": 44, "left": 176}, "words": "188例中国患者)按2:1的比例被随机分配接受阿昔替尼(N=135)或索拉非尼(N=69"}, {"probability": {"variance": 5e-05, "average": 0.996574, "min": 0.96142}, "location": {"width": 847, "top": 393, "height": 44, "left": 177}, "words": "治疗。主要终点无进展生存期(PFS)采用盲法独立中心审核进行评估。次要终点包括"}, {"probability": {"variance": 0.00216, "average": 0.981786, "min": 0.791799}, "location": {"width": 385, "top": 455, "height": 37, "left": 178}, "words": "总生存期(OS)和客观缓解率(ORR)"}, {"probability": {"variance": 0.00024, "average": 0.993402, "min": 0.92979}, "location": {"width": 779, "top": 501, "height": 44, "left": 222}, "words": "本研究入组的患者中,101例患者(49.5%)既往接受过一种含舒尼替尼方案治疗"}, {"probability": {"variance": 6.3e-05, "average": 0.995214, "min": 0.952423}, "location": {"width": 843, "top": 555, "height": 47, "left": 180}, "words": "03例患者(50.5%)既往接受过一种含细胞因子方案治疗。阿昔替尼组和索拉非尼组"}, {"probability": {"variance": 0.000165, "average": 0.994907, "min": 0.919503}, "location": {"width": 838, "top": 613, "height": 41, "left": 179}, "words": "之间的人口统计学和基线特征相似,包括年龄、性别、种族、东部肿瘤协作组(ECOG)"}, {"probability": {"variance": 0, "average": 0.999608, "min": 0.997379}, "location": {"width": 315, "top": 675, "height": 33, "left": 180}, "words": "体力状况、地理区域和既往治疗"}, {"probability": {"variance": 0, "average": 0.714488, "min": 0.714488}, "location": {"width": 36, "top": 669, "height": 36, "left": 871}, "words": "公"}, {"probability": {"variance": 0.003121, "average": 0.981037, "min": 0.715356}, "location": {"width": 853, "top": 713, "height": 54, "left": 224}, "words": "按照治疗总结的既往接受过治疗的患者的PFS见表4。最终PFS分析时OS数据尚"}, {"probability": {"variance": 0.000251, "average": 0.991996, "min": 0.920159}, "location": {"width": 798, "top": 773, "height": 45, "left": 180}, "words": "不成熟。ORR证实阿昔替尼治疗优于索拉非尼治疗(ORR分别为23.7%和10.1%"}, {"probability": {"variance": 3e-05, "average": 0.993996, "min": 0.982113}, "location": {"width": 140, "top": 1585, "height": 25, "left": 544}, "words": "第20页,共27页"}, {"probability": {"variance": 1.3e-05, "average": 0.995418, "min": 0.991877}, "location": {"width": 17, "top": 1618, "height": 19, "left": 275}, "words": "20"}], "language": 3}